{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:51:50Z","timestamp":1793987510287,"version":"4.8.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T00:00:00Z","timestamp":1608768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Extra-intestinal manifestations [EIMs] are frequent in patients with inflammatory bowel diseases [IBD] and are challenging conditions to manage. Tumour necrosis factor alpha antagonists [anti-TNF\u03b1] are recognised as the primary therapeutic option. We aimed to summarise evidence on the efficacy of ustekinumab for the treatment of EIMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched in PubMed, Cochrane Library, and Web of Science, up to October 2020, all interventional and non-interventional studies published in English and assessing ustekinumab efficacy for the treatment of EIMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine studies [eight retrospective and one prospective] were included, enrolling a total of 254 patients with IBD and EIM. Ustekinumab showed its effectiveness for arthralgia and psoriatic arthritis in 152 patients through three high-quality studies. Conversely, no efficacy was found in axial spondyloarthritis. Psoriasis, pyoderma gangrenosum, and erythema nodosum were assessed in seven studies including 65 patients and showed high response rate to ustekinumab treatment. Promising results for aphthous stomatitis and uveitis were reported, but data were limited to 20 patients from two studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ustekinumab showed to be an effective option for the treatment of EIMs, especially for dermatological and rheumatological manifestations. However, more data are needed to confirm the role of ustekinumab in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaa260","type":"journal-article","created":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T07:24:59Z","timestamp":1608362699000},"page":"1236-1243","source":"Crossref","is-referenced-by-count":96,"title":["Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review"],"prefix":"10.1093","volume":"15","author":[{"given":"Lucas","family":"Guillo","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, University Hospital of Marseille Nord, University of Aix-Marseille, Marseille, France"},{"name":"Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"},{"name":"Department of Gastroenterology, Humanitas Clinical and Research Centre - IRCCS, Rozzano Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"},{"name":"Department of Gastroenterology, Humanitas Clinical and Research Centre - IRCCS, Rozzano Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,24]]},"reference":[{"key":"2021070510540270800_CIT0001","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"2021070510540270800_CIT0002","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2021070510540270800_CIT0003","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrgastro.2013.117","article-title":"Extraintestinal manifestations and complications in IBD","volume":"10","author":"Ott","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2021070510540270800_CIT0004","doi-asserted-by":"crossref","first-page":"17463","DOI":"10.3748\/wjg.v20.i46.17463","article-title":"Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients","volume":"20","author":"Zippi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2021070510540270800_CIT0005","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2021070510540270800_CIT0006","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004836-199607000-00009","article-title":"Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients","volume":"23","author":"Veloso","year":"1996","journal-title":"J Clin Gastroenterol"},{"key":"2021070510540270800_CIT0007","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1016\/S1873-9946(13)60660-1","article-title":"Influence of extraintestinal manifestations in health-related quality of life in inflammatory bowel disease patients","volume":"7","author":"Barreiro-de Acosta","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2021070510540270800_CIT0008","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cgh.2016.06.025","article-title":"Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease","volume":"15","author":"Peyrin-Biroulet","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021070510540270800_CIT0009","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2174\/1389450115666140908125453","article-title":"Biologics for extraintestinal manifestations of IBD","volume":"15","author":"Vavricka","year":"2014","journal-title":"Curr Drug Targets"},{"key":"2021070510540270800_CIT0010","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/ibd.20196","article-title":"Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease","volume":"13","author":"Barrie","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"2021070510540270800_CIT0011","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/ecco-jcc\/jjz095","article-title":"Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review","volume":"13","author":"Chateau","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2021070510540270800_CIT0012","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1517\/14712591003724670","article-title":"The use of ustekinumab in autoimmune disease","volume":"10","author":"Ryan","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"2021070510540270800_CIT0013","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial [PHOENIX 1]","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"2021070510540270800_CIT0014","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial [PHOENIX 2]","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"2021070510540270800_CIT0015","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"2021070510540270800_CIT0016","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021070510540270800_CIT0017","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"2021070510540270800_CIT0018","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2021070510540270800_CIT0019","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2021070510540270800_CIT0020","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration","author":"Higgins"},{"key":"2021070510540270800_CIT0021","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"2021070510540270800_CIT0022","author":"Wells"},{"key":"2021070510540270800_CIT0023","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/ecco-jcc\/jjz080","article-title":"Long-term clinical effectiveness of ustekinumab in patients with Crohn\u2019s disease who failed biologic therapies: a national cohort study","volume":"13","author":"Liefferinckx","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2021070510540270800_CIT0024","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jaad.2018.06.065","article-title":"Ustekinumab treatment for neutrophilic dermatoses associated with Crohn\u2019s disease: a multicentre retrospective study","volume":"80","author":"de Risi-Pugliese","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2021070510540270800_CIT0025","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.dld.2019.03.007","article-title":"Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study","volume":"51","author":"Pugliese","year":"2019","journal-title":"Dig Liver Dis"},{"key":"2021070510540270800_CIT0026","doi-asserted-by":"crossref","first-page":"e12811","DOI":"10.1111\/dth.12811","article-title":"Anti-interleukin 12\/23 in the treatment of erythema nodosum and Crohn\u2019s disease: a case report","volume":"32","author":"Spagnuolo","year":"2019","journal-title":"Dermatol Ther"},{"key":"2021070510540270800_CIT0027","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/ajg.2012.42","article-title":"Ustekinumab for peristomal pyoderma gangrenosum","volume":"107","author":"Fahmy","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2021070510540270800_CIT0028","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/ecco-jcc\/jjy200","article-title":"Refractory pyoderma gangrenosum in a patient with Crohn\u2019s disease: complete response to ustekinumab","volume":"13","author":"Nunes","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2021070510540270800_CIT0029","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/ecco-jcc\/jjz167","article-title":"Two cases of successful ustekinumab treatment for non-infectious uveitis associated with Crohn\u2019s disease","volume":"14","author":"Chateau","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2021070510540270800_CIT0030","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/ecco-jcc\/jjaa078","article-title":"Inflammatory cutaneous lesions in inflammatory bowel disease treated with vedolizumab or ustekinumab: an ECCO CONFER multicentre case series","volume":"14","author":"Phillips","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2021070510540270800_CIT0031","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ecco-jcc\/jjz119","article-title":"Ustekinumab for Crohn\u2019s disease: results of the ICC registry, a nationwide prospective observational cohort study","volume":"14","author":"Biemans","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2021070510540270800_CIT0032","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10067-013-2469-y","article-title":"Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results","volume":"33","author":"Gheita","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2021070510540270800_CIT0033","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicentre, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021070510540270800_CIT0034","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study [TOPAS]","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021070510540270800_CIT0035","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1093\/ibd\/izz019","article-title":"Paradoxical arthritis in inflammatory bowel diasease patients on ustekinumab treatment","volume":"25","author":"Garc\u00eda Garc\u00eda","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2021070510540270800_CIT0036","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/kev263","article-title":"Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab","volume":"54","author":"\u010carija","year":"2015","journal-title":"Rheumatology"},{"key":"2021070510540270800_CIT0037","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/bjd.13645","article-title":"Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients","volume":"173","author":"Jones","year":"2015","journal-title":"Br J Dermatol"},{"key":"2021070510540270800_CIT0038","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/j.jaad.2012.04.045","article-title":"Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab","volume":"67","author":"Goldminz","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2021070510540270800_CIT0039","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/dth.12387","article-title":"High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum","volume":"29","author":"Greb","year":"2016","journal-title":"Dermatol Ther"},{"key":"2021070510540270800_CIT0040","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1111\/ajd.12545","article-title":"Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: effectiveness of ustekinumab","volume":"58","author":"Benzaquen","year":"2017","journal-title":"Australas J Dermatol"},{"key":"2021070510540270800_CIT0041","first-page":"2050313X19845206","article-title":"Ustekinumab for the treatment of recalcitrant pyoderma gangrenosum: a case report","volume":"7","author":"Vallerand","year":"2019","journal-title":"SAGE Open Med Case Rep"},{"key":"2021070510540270800_CIT0042","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/ajd.12744","article-title":"Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab","volume":"59","author":"Low","year":"2018","journal-title":"Australas J Dermatol"},{"key":"2021070510540270800_CIT0043","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/archdermatol.2011.168","article-title":"Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab","volume":"147","author":"Guenova","year":"2011","journal-title":"Arch Dermatol"},{"key":"2021070510540270800_CIT0044","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.ophtha.2018.05.014","article-title":"Targeting interleukin-23 in the treatment of noninfectious uveitis","volume":"125","author":"Pepple","year":"2018","journal-title":"Ophthalmology"},{"key":"2021070510540270800_CIT0045","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/BOR.0000000000000619","article-title":"The use of biologics for uveitis associated with spondyloarthritis","volume":"31","author":"Arepalli","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"2021070510540270800_CIT0046","article-title":"Emerging treatment options for extraintestinal manifestations in IBD","author":"Greuter","year":"2020","journal-title":"Gut"},{"key":"2021070510540270800_CIT0047","author":"Janssen Cilag","year":"2020"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaa260\/36180839\/jjaa260.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/15\/7\/1236\/38864858\/jjaa260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/15\/7\/1236\/38864858\/jjaa260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T13:29:46Z","timestamp":1697376586000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/15\/7\/1236\/6046385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,24]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,12,24]]},"published-print":{"date-parts":[[2021,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa260","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2020,12,24]]}}}